Background Rosacea is currently diagnosed by consensus-defined primary and secondary features and managed by subtype. However, individual features (phenotypes) can span multiple subtypes, which has implications for clinical practice and research. Adopting a phenotype-led approach may facilitate patient-centred management. Objectives To advance clinical practice by obtaining international consensus to establish a phenotype-led rosacea diagnosis and classification scheme with global representation. Methods Seventeen dermatologists and three ophthalmologists used a modified Delphi approach to reach consensus on statements pertaining to critical aspects of rosacea diagnosis, classification and severity evaluation. All voting was electronic and blinded. Results Consensus was achieved for transitioning to a phenotype-based approach to rosacea diagnosis and classification. The following two features were independently considered diagnostic for rosacea: (i) persistent, centrofacial erythema associated with periodic intensification; and (ii) phymatous changes. Flushing, telangiectasia, inflammatory lesions and ocular manifestations were not considered to be individually diagnostic. The panel reached agreement on dimensions for phenotype severity measures and established the importance of assessing the patient burden of rosacea. Conclusions The panel recommended an approach for diagnosis and classification of rosacea based on disease phenotype.
Summary
Background Rosacea is currently diagnosed by consensus-defined primary and secondary features and managed by subtype. However, individual features (phenotypes) can span multiple subtypes, which has implications for clinical practice and research. Adopting a phenotype-led approach may facilitate patient-centred management. Objectives To advance clinical practice by obtaining international consensus to establish a phenotype-led rosacea diagnosis and classification scheme with global representation. Methods Seventeen dermatologists and three ophthalmologists used a modified Delphi approach to reach consensus on statements pertaining to critical aspects of rosacea diagnosis, classification and severity evaluation. All voting was electronic and blinded. Results Consensus was achieved for transitioning to a phenotype-based approach to rosacea diagnosis and classification. The following two features were independently considered diagnostic for rosacea: (i) persistent, centrofacial erythema associated with periodic intensification; and (ii) phymatous changes. Flushing, telangiectasia, inflammatory lesions and ocular manifestations were not considered to be individually diagnostic. The panel reached agreement on dimensions for phenotype severity measures and established the importance of assessing the patient burden of rosacea. Conclusions The panel recommended an approach for diagnosis and classification of rosacea based on disease phenotype.
What's already known about this topic?
• Since the 2002 consensus publication from European and North American experts, rosacea diagnosis has been based largely on the presence of more than one of the following primary features: flushing, nontransient erythema, papules/pustules or telangiectasia.
• Secondary features are not considered diagnostic for rosacea, i.e. burning/stinging, plaque, dry appearance, oedema, peripheral location, phymatous changes and ocular manifestations.
• Four common presentations are grouped into subtypes, i.e. erythematotelangiectatic, inflammatory papulopustular, phymatous and ocular rosacea.
What does this study add?
• This study re-evaluates the primary and secondary features of rosacea in order to rationalize diagnosis and classification based on a phenotype approach.
• This study provides a global perspective on rosacea diagnosis and classification with representation from Africa, Asia, Europe, North America and South America.
Rosacea is a chronic inflammatory disease of the skin predominantly affecting the centrofacial region. Although several potential pathways are under investigation, its pathophysiology has yet to be fully determined. So far, dysregulation of the innate (keratinocytes, endothelial cells, macrophages, mast cells, dendritic cells) and adaptive [T helper (Th)1 cells, Th17 cells, plasma cells] immune system has been found. In this dysregulated network, increased levels of antimicrobial peptides, neuropeptides, nitric oxide radical species, proteases, cytokines, chemokines, vascular growth factor (VEGF) along with receptors for cytokines, chemokines, neurotransmitters, VEGF or transient receptor potential ion channels have been detected. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Trigger factors including Demodex and ultraviolet radiation exposure may activate some of these pathways, although the molecular mechanisms are poorly understood thus far. For this reason, no diagnostic laboratory test is available. Therefore, rosacea diagnosis and classification are based on the patient's presenting features. Current diagnostic practice largely follows the recommendations of the National Rosacea Society (NRS) expert panel, which is composed of North American and European dermatologists. According to the NRS system, any one of the following is a primary diagnostic criterion for rosacea: transient erythema, persistent erythema, inflammatory papules/pustules and telangiectasia. 12 Secondary features, which may be present with primary features or appear independently, include phymatous changes, burning or stinging sensations, erythematous plaques, facial dryness and scaling, oedema, peripheral location and ocular manifestations. 12 As multiple features tend to present simultaneously, a subtype classification system was also proposed, grouping the most common presentations as erythematotelangiectatic, inflammatory papulopustular, phymatous and ocular rosacea. This classification is reflected in the majority of subsequent publications on rosacea diagnosis and treatment. [13] [14] [15] [16] [17] [18] [19] [20] [21] Rosacea features can span multiple subtypes ( Fig. 1 A variety of scales are used to measure rosacea severity (Table 1) . 24, 25 Some have been repurposed from other diseases, and despite recent efforts in the field, larger-scale studies and validated scales are required for accurate and consistent severity assessment of individual rosacea features. 26 As clinicians and patients often have disparate views regarding disease severity, 27 objective and practical tools based on individual presenting features are likely to be of value in setting treatment targets and monitoring treatment progress for patients with rosacea. The patient burden of rosacea can be significant. [28] [29] [30] [31] [32] However, few tools exist to measure the psychosocial burden of rosacea and, like severity scales, many are repurposed from other areas, with a variety used across the literature. 32 RosaQoL is the only quality-of-life instrument specific to rosacea. It consists of a 21-item scale but does not cover all disease features (e.g. it omits phymatous changes). 33 The outcome scores also lack an indication of clinically relevant difference.
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Both of these limitations may reduce the usefulness of RosaQoL in clinical practice. The ROSacea COnsensus (ROSCO) panel -comprising dermatologists and ophthalmologists from Africa, Asia (including India, China and Singapore), Europe, North America and South America -is the first to take a global approach to addressing rosacea diagnosis and classification. The aim of this project was to establish international consensus on diagnosis and severity determination in order to improve outcomes for patients with rosacea.
Materials and methods

Expert panel
The expert panel consisted of 17 dermatologists, representing clinical practice in Argentina (n = 1), Brazil (n = 1), Canada (n = 1), China (n = 1), France (n = 1), Germany (n = 2), India (n = 1), Ireland (n = 1), the Netherlands (n = 1), Singapore (n = 1), South Africa (n = 1), the U.K. (n = 1) and the U.S.A. (n = 4). The panel also included three ophthalmologists from Germany (n = 1) and the U.S.A. (n = 2). The process was overseen by two chairpersons from the main panel, who were involved in panel selection and Delphi design (see Supporting Information; File S1 and Fig. S1 ).
The modified Delphi approach
The Delphi process is an egalitarian method of establishing expert consensus on complex issues. It has previously demonstrated usefulness in health care and other industries and is considered a robust method of reaching consensus. [34] [35] [36] [37] [38] The ROSCO panel used a modified Delphi process, consisting of e-surveys and a group meeting (Fig. 2) . A literature review of 73 unique references was conducted to inform the e-survey and meeting content (see Supporting Information; Tables S1 and S2). The dermatologist panel completed a series of three e-surveys, followed by a 2-day meeting in February 2016. All dermatologists completed the e-surveys and contributed at the meeting (some attended remotely and not all of the questions were answered by all of the panellists). The ophthalmologists completed a separate series of two e-surveys on ocular rosacea. All ophthalmologists completed the ocular e-surveys; in addition, one ophthalmologist also completed the dermatology e-surveys and participated at the meeting (see Supporting Information; Table S3 ).
Questionnaire development and administration
Consensus statements were structured to assess the level of agreement using the terms 'strongly disagree', 'disagree', 'agree' or 'strongly agree'. Consensus was defined as achievement of ≥ 75% 'agree' or 'strongly agree'. Some questions were open-ended to allow for the development of consensus statements in a subsequent round of voting.
Meeting process
Items not achieving consensus at the e-survey stage were discussed at the meeting. The panel received an overview of each topic from the chairpersons, followed by workshop exercises on rosacea diagnosis, classification, severity and psychosocial burden. After each workshop, consensus statements were constructed and a vote was taken. Voting was conducted by keypads and the panel was blinded to individual votes. If consensus was not reached, the panel held a further discussion, refined the statement and voted again.
Results
Consensus recommendations
Consensus statement voting is given in brackets [e.g. 15 of 17 voted 'agree' or 'strongly agree'. Full statements are available in the Supporting Information (see Supporting Information; Table S3 )]. Elements that were considered, but not voted on, are described in 'Discussion points' below. 
Diagnosis and classification of rosacea
Consensus statements
Discussion points
If either flushing/transient erythema, inflammatory papules/ pustules, telangiectasia or ocular manifestations were present, the addition of any other major phenotype could be diagnostic of rosacea.
Flushing/transient erythema A careful history should be taken to assess flushing/transient erythema during diagnosis of rosacea as a whole, as this feature may not be visibly apparent during consultation. As per persistent erythema, flushing/transient erythema in rosacea should occur in a centrofacial location in order to be considered a major feature of rosacea.
Telangiectasia Telangiectases are a major feature of rosacea if steroid use and sun damage can be excluded. Age of onset should also be considered. Additionally, centrofacial distribution of telangiectasia, excluding perinasal telangiectases (which are almost universal in adults), is required.
Inflammatory lesions Inflammatory lesions consist of inflammatory papules/pustules and exclude comedones, although the presence of comedones may not exclude a diagnosis of rosacea as acne and rosacea can coexist. Drug and immunosuppression history is important to determine whether inflammatory papules/pustules are a result of rosacea. Eczema, drug reactions, demodicidosis, seborrhoeic dermatitis and lupus should be excluded.
Darker skin types
The panel acknowledged the difficulties in diagnosing rosacea in darker skin types. It was discussed that erythema and telangiectasia may not be visible in skin phototypes V and VI, an issue that may be overcome with experience and appropriate history taking (e.g. greater emphasis on hyperpigmentation and symptoms of irritation, such as burning and stinging). Other techniques, including skin biopsy, can also be considered for diagnostic support.
Developing rosacea severity scales
Consensus statements
The panel agreed that the severity of each feature should be rated independently, rather than grouped into subtype (14 of 18). For example, a patient could have rosacea with mild persistent erythema and moderate inflammatory papules/pustules or rosacea with moderate flushing and severe phymatous changes. There was consensus that effective and validated scales are required in rosacea to help clinicians objectively assess the severity of individual features (14 of 18). It was further agreed that cutaneous rosacea features should be evaluated based on a categorical scale (17 of 18) and that feature severity should be assessed using a 5-point categorical scale that includes 'clear/none' and 'almost clear/minimal' as these two grades are of unequivocal clinical relevance, in addition to 'mild', 'moderate' and 'severe' (18 of 18). A scale to assess the severity of each phenotype was discussed and the dimensions that should be included for each are given in Table 3 . These statements provide a foundation for the severity scales for each phenotype.
Discussion points
The panel noted that rosacea intensity can vary across a natural cycle and this should be considered when taking a history. In addition, the timing of assessment should be reflective of a patient's true severity levels (i.e. in the absence of trigger factors as far as is possible).
However, there was also consideration that scales for each feature may not be relevant for every patient. In addition, scales are required that can be validated in patients with darker skin phototypes.
The panel also discussed that a patient-rated scale to capture the intensity of the patient's presenting features should be considered in clinical practice.
Ocular rosacea: the ophthalmologist's perspective
The clinical grading of ocular rosacea is described in Table 4 . A minimum combination of ocular features for a diagnosis of rosacea was considered to be either both lid margin telangiectasia and interpalpebral injection, or corneal abnormalities and scleral inflammation. Further results from the surveys are given in the Supporting Information (see Supporting Information; Table S3 ). It is important to note that the recommendations may not be generalizable as only three ophthalmologists were involved.
The patient burden of rosacea
Consensus statements
Consensus was achieved on the following statements: the psychosocial impact of living with rosacea can adversely impact an individual's well-being (17 of 18) and that the level of psychological burden of rosacea should influence treatment decisions (17 of 18). Of importance for clinical practice, physicians should routinely enquire about the psychosocial impact of rosacea (16 of 16). The panel concluded that the development of a practical tool to measure psychosocial impact for patients with rosacea is needed (17 of 17) and that psychosocial impact warrants further investigation (15 of 15).
Discussion points
More research is still needed regarding the major psychosocial impact of rosacea. However, a number of comorbid conditions, including poor self-esteem, social isolation, depression and anxiety, should be considered for the development of a novel tool. Furthermore, there was agreement that a new tool should go beyond those currently available and assess the psychosocial impact for all major phenotypes (including phymatous changes, which is absent from the RosaQoL).
In addition, there is also a psychosocial impact associated with rosacea treatments. For example, patients can become disheartened as a result of the need for ongoing treatment, medication costs and high expectations. Furthermore, requirements to reduce trigger factor exposure can lead to lifestyle limitations.
When determining the psychosocial impact of rosacea, it is both necessary and important to assess treatment expectations and treatment burden. It was also noted that patient-focused messages around psychosocial impact are important to ensure successful management.
Treatment goal setting
Treatment goals in rosacea should be based on discussion of severity and the psychosocial burden and should include the following:
• Achieving clear/almost clear skin (15 of 17) • A reduction in severity of features (17 of 17) • A reduction in frequency of flares (17 of 17) • An improvement in patient-reported features (visible and nonvisible) (17 of 17) • Achieving patient satisfaction with treatment (17 of 17) • A reduction in the impact of rosacea on the patient (17 of
17)
The majority of panellists agreed that they would treat an individual feature when it bothered the patient, regardless of severity.
Discussion
This project incorporated the opinions of a global panel of dermatologists using a modified Delphi method. There are some limitations to consider within the Delphi process, most notably that the majority of voting relied on clinical opinion and there may have been good evidence contradicting a particular statement. Some researchers have expressed concerns over bias and reproducibility in the Delphi process, stating that it is not necessarily an 'evidence-based' process as it relies on clinical opinion. 39, 40 However, the Delphi process is exploratory in nature and is therefore not recommended for use in areas with abundant theory or evidence, or where topics are already well defined. 41 It is also considered to be well suited for informing judgement on issues that are difficult to define, expertise specific and future orientated, 41 such as those addressed in the present paper. The ROSCO project attempted to overcome concerns over bias as far as possible, through the use of blinded voting and by considering evidence in the published literature where available. The panel has future work planned to facilitate adoption of a phenotype-led approach in the clinic and in research, with a focus on practical tool development.
The present ROSCO panel recommendations for phenotypeled rosacea diagnosis provide a strong foundation for further developments. Specific guidance on rosacea diagnosis according to both presenting feature combinations and patient history would be of particular value, potentially in the form of an algorithm.
Validated scales to assess individual feature severity and psychosocial burden are a key area of future work for ROSCO. Patients should be involved during scale development to ensure maximum relevance for those directly affected by the disease. Other groups, such as the Harmonizing Outcome Measures for atopic Eczema (HOME) initiaive, 42 have already successfully involved patients in clinical tool development and use a model that may prove to be beneficial to the ROSCO panel.
Further work is needed for ocular rosacea. Potential future directions include screening guidance for dermatologists, which would benefit from greater ocular specialist involvement in the panel. The panel recommends a phenotype approach to rosacea diagnosis, severity grading and management. As individual treatments do not address multiple features simultaneously, consideration of specific phenotypical issues facilitates individualized optimization of rosacea management. Furthermore, the panel recommend patient-focused goal setting and the development of a novel psychosocial tool to evaluate the burden of rosacea in patients of all skin types.
Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher's website:
File S1. Literature search. Fig S1. Literature search methodology. Table S1 . Search terms. Table S2 . List of publications retrieved. Table S3 . Consensus statements and results. Video S1. Author video.
